Topic: transcatheter aortic valve replacement
Medtronic aims to boost its growth with a suite of new products including surgical robotics, diabetes hardware and miniaturized pacemakers.
The FDA broadened its approvals of several transcatheter aortic valve replacements to include patients at a low risk of surgical complications.
Boston Scientific received approval for its heart valve on the eve of its first-quarter report and after the FDA halted its sales of surgical mesh.
Saranas got a de novo clearance from the FDA for its Early Bird system, used to detect internal bleeding in real time during endovascular procedures.
Boston Scientific plans to buy Claret Medical for $220 million upfront, including its safety-net device that catches debris from TAVR procedures.
The results indicate improved outcomes at the five-year mark for patients implanted with the CoreValve transcatheter aortic valve replacement device.
Boston Scientific said it was delaying the commercial release in the U.S. and Europe of its Lotus Edge aortic valve system.
Shockwave's new financing will expand commercialization of its ultrasound balloon treatment for calcified artery disease and boost R&D.
Boston Scientific started 2016 strong thanks to double-digit growth in four businesses: Endoscopy, Urology and Pelvic Health, Interventional Cardiology and Peripheral Intervention. In June, it announced a global restructuring program to support long-term objectives.
Medtronic scored FDA approval and a CE mark for its Avalus valve for the surgical treatment of aortic valve disease.